Gammacell Irradiator with caesium 137 source

带铯 137 源的 Gammacell 辐照器

• 批准号: 6730867
• 负责人: Ruth S Nussenzweig
• 金额: $ 12.53万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-04-01 至 2005-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6730867
• 关键词: biomedical equipment; biomedical equipment purchase; cesium; gamma radiation; radiation immunosuppression

DESCRIPTION (provided by applicant): This is an application for a Gammacell irradiator, containing a caesium source. It is to substitute for our current one, purchased more than 30 years ago, of which the caesium source has decayed greatly. This instrument is used several times a week by a large number of faculties of the Departments of Medical and Molecular Parasitology and Pathology, and others at NYU School of Medicine, which has the largest number of investigators working on malaria vaccine development in an Academic Institution in the U.S. In addition, several HIV investigators of the Department of Medicine at NYU School of Medicine, and Veterans Affairs use this source of irradiation. The universally recognized "gold standard of protective anti-malaria immunity," i.e. the immunization of mice with irradiated sporozoites, is a necessary control for the development of all pre-erythrocytic vaccine candidates. Currently, it takes much too long a time to attenuate sporozoites of rodent malaria (45 minutes), which meanwhile lose their infectivity and immunogenicity. Protective anti-malaria immunity will be explored by the following approaches: a) immunization with a recombinant Yellow Fever Vaccine (17D) expressing sequence of the CS protein; b) extend the duration of a NYU/Apovia vaccine candidate currently in Phase I trials; c) elucidation of the effect of human NKT cells on plasmodial liver stages, and the adjuvant activity of a-galactosylceramide in enhancing anti-malaria and anti- HIV immune responses; d) determine whether vaccination against sporozoites influences the migration of sporozoites from the skin to the blood; e) Determine the relationship of apoptotic death of hepatocytes by infection with irradiated sporozoites to the initiation of a protective anti malaria immune response mediated by dendritic cells; f) define the immune response and the respective malaria antigens operating in transgenic mice made tolerant to CS, and the immune response to immunization with early exo-erythrocytic generated in vitro in the absence of host cells; g) is an HIV related project aiming to clarify how anti-CD4+ binding antibodies interfere with gp 120 presentation.

描述（由申请人提供）：这是一个Gammacell辐照器的申请，包含铯源。它将取代我们目前的一个，30多年前购买的，其中铯源已经大大衰变。该仪器每周被医学和分子寄生虫学和病理学系的大量院系以及纽约大学医学院的其他院系使用几次，纽约大学医学院拥有美国学术机构中最多的疟疾疫苗开发研究人员。和退伍军人事务部使用这种辐射源。普遍公认的“保护性抗疟疾免疫的黄金标准”，即用辐照的子孢子免疫小鼠，是开发所有红细胞前疫苗候选物的必要对照。目前，减毒啮齿动物疟疾的子孢子需要太长的时间（45分钟），同时失去其感染性和免疫原性。 保护性抗疟疾免疫将通过以下方法来探索：a）用表达CS蛋白序列的重组黄热病疫苗（17 D）免疫; B）延长目前处于I期试验的NYU/Apovia疫苗候选物的持续时间; c）阐明人NKT细胞对疟原虫肝脏阶段的影响，以及α-半乳糖神经酰胺在增强抗疟疾和抗HIV免疫应答中的佐剂活性; d）确定针对子孢子的疫苗接种是否影响子孢子从皮肤向血液的迁移; e）确定照射子孢子感染引起的肝细胞凋亡死亡与树突状细胞介导的保护性抗疟疾免疫反应启动的关系; f）确定在对CS耐受的转基因小鼠中起作用的免疫应答和相应的疟疾抗原，以及在不存在宿主细胞的情况下对体外产生的早期红细胞外免疫的免疫应答; g）是HIV相关项目，旨在阐明抗CD 4+结合抗体如何干扰gp 120呈递。